A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXijing Hospital

About this trial

This is a prospective, open-label, single-center clinical study targeting renal cell carcinoma. Sixty patients with a high clinical suspicion of renal cell carcinoma were included. Qualified subjects will undergo 68Ga-NOTA-RCCB6 PET/CT examination. The aim is to establish the optimal imaging protocol; evaluate the distribution characteristics and correlations of physiological and pathological positive uptake, and using pathological results as the gold standard, assess the diagnostic efficacy of 68Ga-NOTA-RCCB6 PET/CT in renal cell carcinoma.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Sequential

Treatments tested in this trial

  • 68Ga-NOTA-RCCB6 PET/CT Scan

    Diagnostic test

    The imaging agent 68Ga-NOTA-RCCB6 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations. Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection. The maximum mass dose of CD70 should not exceed 240ug, and the maximum volume of administration should not exceed 5 mL.

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: before-after study in the same patientExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Maximum Standardized uptake value (SUVmax)

Maximum Standardized uptake value (SUVmax) of \[68Ga\]RCCB6 and \[68Ga\]PSMA in the included subjects' primary and/or metastatic lesions.

Time frame
1 day from injection of the tracer
2

Mean Standardized Uptake Value(SUVmean) of liver

Mean Standardized uptake value (SUVmean) of \[68Ga\]RCCB6 and \[68Ga\]PSMA in the included subjects' liver.

Time frame
1 day from injection of the tracer
3

Tumor to Background Ratio(TBR)

TBR=SUVmax/SUVmean

Time frame
1 day from injection of the tracer
4

The correlation between CD70 expression and [18F]RCCB6 uptake value

The Standardized uptake value (SUV) of \[68Ga\]RCCB6 will be calculated, and the correlation between pathological results and tumor uptake of \[68Ga\]RCCB6 will be analyzed.

Time frame
30 days from injection of the tracer

Secondary outcomes

1

Diagnostic value of 68Ga-NOTA-RCCB6 PET/CT in patients with RCC

We will calculate the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of 68Ga-NOTA-RCCB6 PET/CT in patients with RCC. We will also compare the diagnostic value of \[68Ga\]RCCB6 with \[68Ga\]PSMA. All the above goals will be achieved by analyzing the 68Ga-NOTA-RCCB6 PET/CT and 68Ga-PSMA PET/CT imaging data.

Time frame
3-6 months from injection of the tracer

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.